Advances in sodium-glucose cotransporter-2 inhibitors for improving skeletal muscle metabolism and function

doi:10.16352/j.issn.1001-6325.2026.02.0278

Abstract

Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are guideline-recommended medications for type 2 diabetes mellitus and chronic heart failure. Increasing attention is being paid to the effects of SGLT2is on body composition, including adipose tissue and skeletal muscle, with particular emphasis on the latter. SGLT2is improve skeletal muscle function through multiple mechanisms: enhancing glucose, fatty acid, and amino acid metabolism in skeletal muscle; suppressing the expression of atrophy pathway-related molecules; and alleviating oxidative stress and inflammatory responses in skeletal muscle. Collectively, these findings provide clinicians with novel diagnostic and therapeutic perspectives for managing elderly patients with chronic diseases accompanied by skeletal muscle atrophy.

Key words: sodium-glucose cotransporter 2 inhibitors, skeletal muscle

CLC Number:

R592

SHI Jingwen, WANG Yabing, SUN Ying. Advances in sodium-glucose cotransporter-2 inhibitors for improving skeletal muscle metabolism and function[J]. Basic & Clinical Medicine, 2026, 46(2): 278-281.

References

[1]Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial[J]. Nat Med, 2021, 27: 1954-1960.
[2]Jhung PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF[J]. Circulation, 2021, 143: 298-309.
[3]Hashimoto Y, Takahashi F, Okamura T, et al. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes[J]. Metabolism, 2023, 144: 155585. doi: 10.1016/j.metabol.2023.155585.
[4]Dicola S, D′amico G, Caraceni P, et al. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis[J]. J Hepatol, 2024, 81: 641-650.
[5]Zeng F, Jiang W, Chang X, et al. Sarcopenia is associated with short- and long-term mortality in patients with acute-on-chronic liver failure[J]. J Cachexia Sarcopenia Muscle, 2024, 15: 1473-1482.
[6]Latvarasku A, Rebelos E, Tuisku J, et al. SGLT2 inhibitor dapagliflozin increases skeletal muscle and brain fatty acid uptake in individuals with type 2 diabetes: a randomized double-Blind placebo-controlled positron emission tomography study[J]. Diabetes Care, 2024, 47: 1630-1637.
[7]Gao Q, Jiang Y, Song Z, et al. Dapagliflozin improves skeletal muscle insulin sensitivity through SIRT1 activation induced by nutrient deprivation state[J]. Sci Rep, 2024, 14: 16878. doi: 10.1038/s41598-024-67755-7.
[8]Conte E, Imbrici P, Dinoi G, et al. SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure[J]. Eur J Pharmacol, 2025, 997: 177617. doi: 10.1016/j.ejphar.2025.177617.
[9]Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice[J]. EBioMedicine, 2017, 20: 137-149.
[10]Wood N, Straw S, Cheng CW, et al. Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction[J]. Eur J Heart Fail, 2024, 26: 925-935.
[11]Zhang L, Lin H, Yang X, et al. Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats[J]. Biomed Pharmacother, 2023, 169: 115852. doi: 10.1016/j.biopha.2023.115852.
[12]Radlinger B, Ress C, Folie S, et al. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis[J]. Diabetologia, 2023, 66: 754-767.
[13]Winzer EB, Schauer A, Langner E, et al. Empagliflozin preserves skeletal muscle function in a HFpEF rat model[J]. Int J Mol Sci, 2022, 23: 10989. doi: 10.3390/ijms231910989.
[14]Kawakami R, Matsui H, Matsui M, et al. Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice[J]. Sci Rep, 2023, 13: 18025. doi: 10.1038/s41598-023-45390-y.
[15]Huang Q, Chen J, Liao S, et al. The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway[J]. Biogerontology, 2024, 25: 567-581.
[16]Tanaka K, Takahashi H, Katagiri S, et al. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice[J]. Am J Physiol Endocrinol Metab, 2020, 318: e492-e503.
[17]Nakamura S, Miyachi Y, Shinjo A, et al. Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus[J]. J Cachexia Sarcopenia Muscle, 2023, 14: 2866-2881.
[18]Lv XH, Cong XX, Nan JL, et al. Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice[J]. Acta Pharmacol Sin, 2022, 43: 2651-2665.
[19]Macdonald TL, Pattamaprapanont P, Cooney EM, et al. Canagliflozin prevents hyperglycemia-associated muscle extracellular matrix accumulation and improves the adaptive response to aerobic exercise[J]. Diabetes, 2022, 71: 881-893.
[20]Bamba R, Okamura T, Hashimoto Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice[J]. J Cachexia Sarcopenia Muscle, 2022, 13: 574-588.
[21]Xie K, Sugimoto K, Tanaka M, et al. Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats[J]. J Clin Biochem Nutr, 2023, 72: 248-255.
[22]Yang X, Wang L, Zhang L, et al. Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats[J]. Diabetol Metab Syndr, 2023, 15: 154. doi: 10.1186/s13098-023-01130-w.
[23]彭晴怡,许岭翎.1型糖尿病诱发肌少症的研究进展[J].基础医学与临床,2024,44:1189-1193.